Claims for Patent: 8,461,211
✉ Email this page to a colleague
Summary for Patent: 8,461,211
| Title: | Use for budesonide and formoterol |
| Abstract: | The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease. |
| Inventor(s): | Bauer; Carl-Axel (Lund, SE), Trofast; Jan (Lund, SE) |
| Assignee: | AstraZeneca AB (Sodertalje, SE) |
| Application Number: | 12/982,360 |
| Patent Claims: |
1. A method for treating a patient suffering from chronic obstructive pulmonary disease (COPD), the method comprising administering to the patient via inhalation a
composition comprising formoterol fumarate dihydrate and budesonide.
2. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 1 to 50 .mu.g formoterol fumarate dihydrate and 45 to 2200 .mu.g budesonide. 3. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 3 to 30 .mu.g formoterol fumarate dihydrate and 45 to 2200 .mu.g budesonide. 4. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 4.5 or 9 .mu.g formoterol fumarate dihydrate. 5. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 80, 160, or 320 .mu.g budesonide. 6. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 4.5 .mu.g formoterol fumarate dihydrate and 80 or 160 .mu.g budesonide. 7. The method of claim 1, wherein the composition is administered to the patient in up to four unit doses per day, each unit dose delivering to the patient 4.5 .mu.g formoterol fumarate dihydrate and 160 .mu.g budesonide. 8. The method of claim 1, wherein the composition is administered to the patient in one or two unit doses per day, each unit dose delivering to the patient 9 .mu.g formoterol fumarate dihydrate and 320 .mu.g budesonide. 9. The method of claim 1, wherein the composition is in the form of a dry powder and is administered from a dry powder inhaler. 10. The method of claim 1, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. 11. The method of claim 1, wherein the composition is administered via a nebulizer. 12. The method of claim 1, wherein the formoterol fumarate dihydrate and budesonide are in the form of particles of a size less than 10 .mu.m. 13. The method of claim 2, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. 14. The method of claim 3, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. 15. The method of claim 4, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. 16. The method of claim 5, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. 17. The method of claim 6, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. 18. The method of claim 7, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. 19. The method of claim 8, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. 20. The method of claim 12, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler. |
